Getinge Hires Stacy Beske as Acute Care Head

Stacy Beske, formerly of Philips, will lead Getinge's acute care therapies unit starting December 1 as predecessor Elin Frostehav departs for Vitrolife Group.

Updated on Nov. 10, 2026 in People

Getinge Hires Stacy Beske as Acute Care Head

Getinge has hired Stacy Beske as president of acute care therapies, announced in a company statement on Monday. Beske, who joins from Philips, replaces Elin Frostehav, who is leaving to become CEO of Vitrolife Group.

Why it matters

The acute care therapies unit accounted for more than half of Getinge's net sales in the first nine months of the year, and its growth has lagged the company's other businesses. The leadership change comes as the company works to address acute care quality challenges.

The acute care therapies unit generated more than half of Getinge's net sales over the first nine months of the year, but its sales and order intake grew more slowly than the company's other businesses. The extraction does not specify the exact growth rates for the unit.

The players

Getinge

Getinge is a Swedish medical technology company that makes equipment for operating rooms, intensive care, and acute care settings.

Stacy Beske

Stacy Beske is a medtech executive with a Ph.D. in cardiovascular physiology and prior leadership roles at Medtronic and Philips.

Elin Frostehav

Elin Frostehav is the outgoing president of Getinge's acute care therapies unit, departing to lead Vitrolife Group.

Vitrolife Group

Vitrolife Group is a medtech company focused on reproductive health products and services.

The details

Beske previously served as business unit leader for image guided therapy devices at Philips and holds a Ph.D. in cardiovascular physiology. She spent more than 18 years at Medtronic before joining Philips. Beske will take over the role on December 1.

Timeline

  1. Monday: Getinge announces Beske's hire

  2. December 1: Beske takes over as president of acute care therapies

  3. 2024: FDA advises healthcare professionals to transition away from Cardiosave and Cardiohelp devices

Market Landscape

Getinge's acute care therapies unit has faced regulatory pressure, including a 2024 FDA advisory to transition away from its Cardiosave and Cardiohelp devices. The hire of an executive with prior cardiovascular and imaging-device experience at Philips and Medtronic comes as the unit's growth trails the company's other businesses.

For hospitals and clinicians who rely on Getinge's acute care equipment, the leadership transition may affect product support and strategy going forward. The extraction does not indicate any immediate change to product availability or pricing.

The takeaway

Leadership changes at large medtech companies often signal shifts in strategy for lagging business units, and Getinge's acute care unit will be watched as Beske takes charge. Readers following the company should track whether its growth trajectory improves under new leadership.

Further reading

Explore more executive moves in our People section.

Source note: This article includes information reported by MedTech Dive.